|Articles|October 1, 2014
Dana-Farber Leads Kadcyla ATEMPT Study in HER2-Positive Breast Cancer
Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.
Advertisement
Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Mariska Hargitay Honors Father Through Myeloma Awareness Effort
2
Monjuvi, Revlimid Combo May Help Prevent Diffuse Large B-Cell Lymphoma Relapse
3
Trodelvy Plus Keytruda Shows Lasting Benefit in Metastatic Breast Cancer
4
Changing Surveillance Routines Brings New Survivorship Challenges
5